Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab

Dermatitis. 2023 Jan-Feb;34(1):58-59. doi: 10.1089/DERM.0000000000000954.

Authors

Ling Yu^{1

2}, Jianbo Wang¹, Lu Bian¹, Zhenlu Li¹, Ming Li³, Jianguo Li¹, Shoumin Zhang¹

Affiliations

¹ From the Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou.
² Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing.
³ Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

PMID: 36705654
DOI: 10.1089/DERM.0000000000000954

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Epidermolysis Bullosa Dystrophica* / drug therapy
Humans
Skin

Substances

dupilumab
Antibodies, Monoclonal, Humanized

Supplementary concepts

Epidermolysis Bullosa Pruriginosa